2. TGF-beta/Smad
  3. TGF-β Receptor
  4. LDN193189

LDN193189  (Synonyms: DM-3189)

Cat. No.: HY-12071 Purity: 99.42%
COA Handling Instructions

LDN193189 is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva.

For research use only. We do not sell to patients.

LDN193189 Chemical Structure

LDN193189 Chemical Structure

CAS No. : 1062368-24-4

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
5 mg USD 84 In-stock
10 mg USD 108 In-stock
50 mg USD 288 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 43 publication(s) in Google Scholar

Other Forms of LDN193189:

LDN193189 Related Antibodies

Top Publications Citing Use of Products

41 Publications Citing Use of MCE LDN193189

IHC
WB

    LDN193189 purchased from MCE. Usage Cited in: Oxid Med Cell Longev. 2020 Jun 8;2020:4175613.  [Abstract]

    Western blot and grey analysis of CYP11a1, CYP19a1, BCL2, CALR, CHOP, caspase3, caspase12, PERK, and GRP78. qRT-PCR analyzed ATF4, caspase3, and GRP78 mRNAs. The relieving function of BMP4 on ER stress is diminished after blockade of BMP receptor I (BMPRI) with DM-3189.

    LDN193189 purchased from MCE. Usage Cited in: Cardiovasc Toxicol. 2019 Jun;19(3):264-275.  [Abstract]

    H9c2 cells are treated as following: control, DOX, DOX + rhBMP (Bmpr1a agonist) and DOX + LDN193189 (Bmpr1a inhibitor). Cells with red fluorescence indicate favorable MMP while green fluorescence indicates damage.

    View All TGF-β Receptor Isoform Specific Products:

    View All Isoforms
    ALK1 ALK2 ALK3 ALK4 ALK5 ALK6 ALK7 ACVR2A ACVR2B

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    LDN193189 is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva[1][2][3].

    IC50 & Target[1]

    ACVR1

    5 nM (IC50)

    BMPR1A

    30 nM (IC50)

    In Vitro

    LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively[1].
    LDN-193189 has weake effects on activin and the TGF-β type I receptors ALK4, ALK5 and ALK7 with IC50 values of ≥ 500 nM[1].
    LDN-193189 binds ActRIIA with Kd value of 14 nM[2].
    LDN-193189 (0.5 μM; 30 min) targets GDF8 induced Smad2/3 signaling and repression of myogenic transcription factors[2].
    LDN-193189 (0.05, 0.5, 5 μM) efficiently inhibits GDF8 induced Smad3/4 reporter gene activity[2].
    LDN-193189 (0-5 μM) rescues myogenesis in myoblasts treated with GDF8[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    LDN193189 Related Antibodies

    Western Blot Analysis[2]

    Cell Line: Primary human myoblasts, C2C12 cells
    Concentration: 0.5 μM
    Incubation Time: 30 min
    Result: Inhibited GDF8-induced signaling pathways in undifferentiated and in differentiated primary human myoblasts and in C2C12 premyoblasts.
    In Vivo

    LDN-193189 (i.p.; 3 mg/kg; daily; for 35 days) might affect the interaction between breast cancer cells and the bone environment[3].
    LDN-193189 (i.p.; 3 mg/kg; single) shows a reduction in ectopic ossification and functional impairment[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Ahymic NMRI nude female mice (6-week-old)[3]
    Dosage: 3 mg/kg
    Administration: Itraperitoneal, daily, for 35 days
    Result: Ehanced etastases development in vivo.
    Animal Model: C57BL/6 mice[1]
    Dosage: 3 mg/kg
    Administration: Intraperitoneal, single
    Result: Diminished ectopic bone formation and preserved joint spaces over the same interval without inducing fractures, osteopenia or skeletal abnormalities.
    Molecular Weight

    406.48

    Appearance

    Solid

    Formula

    C25H22N6
    CAS No.
    SMILES

    C1(C2=C3N=CC(C4=CC=C(N5CCNCC5)C=C4)=CN3N=C2)=CC=NC6=CC=CC=C16
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : 12 mg/mL (29.52 mM; ultrasonic and adjust pH to 2 with HCl)

    H2O : < 0.1 mg/mL (insoluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.4601 mL 12.3007 mL 24.6015 mL
    5 mM 0.4920 mL 2.4601 mL 4.9203 mL
    10 mM 0.2460 mL 1.2301 mL 2.4601 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 1.2 mg/mL (2.95 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 1.2 mg/mL (2.95 mM); Clear solution

    *All of the co-solvents are available by MCE.
    Purity & Documentation

    Purity: 99.48%

    COA (254 KB) LCMS (89 KB)

    Handling Instructions (2659 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    LDN193189 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Keywords:

    LDN1931891062368-24-4DM-3189LDN 193189LDN-193189DM3189DM 3189TGF-β ReceptorTransforming growth factor beta receptorsbone morphogenetic protein (BMP)BMP I receptortranscriptionALK2ALK3bone morphogenetic protein signallingfibrodysplasia ossificans progressivaInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    LDN193189
    Cat. No.:
    HY-12071
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.